New York, April 17, 2024 - PRISM MarketView - Lexaria Bioscience (Nasdaq: LEXX) has received approval from an independent third-party ethics review board for its human pilot study #2 investigating GLP-1 drugs in combination with Lexaria’s DehydraTECH technology. Lexaria will begin recruiting subjects for the study immediately, and expects to dose the first patient within 30 days. The company’s share price rose more than 16% in intraday trading following the news.
The study will be performed in up to nine healthy volunteers and will study a single 7 mg dose of Rybelsus® (semaglutide) against two different, concentration-matched 7 mg DehydraTECH-enabled semaglutide formulations from crushed Rybelsus®.
The second arm of the study will investigate an oral dissolvable tablet formulation, also compliant with the FDA IID, with DehydraTECH-powered semaglutide from Ryblesus®.
“The Lexaria scientific team believes that a dissolvable oral tablet that delivers an effective fraction of semaglutide along with reduced side effects could potentially offer valuable benefits to the pharmaceutical industry that might lead to a higher likelihood of favorable strategic partnering with leading industry players in GLP-1.”
Chris Bunka, CEO of Lexaria
GLP-1 drugs are well-established medicines that have demonstrated long-term safety, but are linked to adverse gastrointestinal reactions including diarrhea, nausea, and vomiting. Between 5% and 10% of patients discontinue use of a GLP-1 due to these side effects, and a study of more than 10,000 patients found that 56% “prefer oral medication over injections”.
“Most GLP-1 drugs sold today are administered by painful and expensive injection devices. More effective and tolerable oral delivery of GLP-1 drugs could be extremely valuable to patients and to industry."
Chris Bunka, CEO of Lexaria
Lexaria expects to complete the study mid-year.
About Lexaria Bioscience Corp. & DehydraTECH
DehydraTECH™ is Lexaria’s patented drug delivery formulation and processing platform technology which improves the way active pharmaceutical ingredients (APIs) enter the bloodstream through oral delivery. Since 2016, Lexaria has developed and investigated DehydraTECH with a variety of beneficial molecules in oral and topical formats. DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption and has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier, which Lexaria believes to be of particular importance for centrally active compounds. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 41 patents granted and many patents pending worldwide. For more information, please visit www.lexariabioscience.com.
Lexaria Bioscience (Nasdaq: LEXX) is featured on PRISM Emerging Public Health Index
About PRISM MarketView:
Established in 2020, PRISM MarketView is dedicated to the monitoring and analysis of small cap stocks in burgeoning sectors. We deliver up-to-the-minute financial market news, provide comprehensive investor tools and foster a dynamic investor community. Central to our offerings are proprietary indexes that observe emerging sectors, including biotech, clean energy, next-generation tech, medical devices and beyond. Visit us at prismmarketview.com and follow us on Twitter.
Disclaimer:
PRISM MarketView is not a registered or licensed broker-dealer or investment adviser and does not offer investment advice. The information provided in this communication is not intended to constitute an offer to sell, a solicitation of an offer to buy, or a recommendation for any security.
Contact:
Prism MarketView | Stock Market News & Investment Opportunities
PRISM MarketView - Social Media (X)